Skip to Content
Upcoming Webinar

New Horizon for ALK-rearranged NSCLC Patients: lorlatinib

Date: October 27, 2025 | 2:00 PM
When: Monday, October 27 | 2 p.m. EST
Presenters:
Kaiwen Wang, PharmD, BCOP (The University of Texas MD Anderson)

The treatment landscape for metastatic non–small cell lung cancer keeps evolving—and so does the evidence guiding targeted therapy decisions. This session brings together two oncology pharmacists to unpack the latest data and share how these updates translate into real-world care, from efficacy insights to AE management and dose modification.

Kaiwen Wang, PharmD, BCOP, will dive into the latest data and best practices in managing patients receiving lorlatinib for ALK+ metastatic NSCLC. This session reviews long-term survival and intracranial efficacy data, common adverse events, and practical strategies for managing side effects and dose modification to optimize outcomes.

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.